newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

  • RenovoRx, Inc. (NASDAQ: RNXT) will participate in a JonesTrading webinar on August 13, 2026, at 1:30 p.m. ET featuring CEO Shaun Bagai & oncology key opinion leaders.
  • The webinar titled "The Evolving Pancreatic Cancer Landscape" will be moderated by Justin Walsh of JonesTrading & include speakers Dae Won Kim of Moffitt Cancer Center & Ravi Shridhar of AdventHealth Cancer Institute.
  • Discussion topics include the TAMP platform enabled by the RenovoCath device for local chemotherapy delivery & the ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine for locally advanced pancreatic cancer.
  • RenovoRx reported $1.1 million in RenovoCath sales for the full year 2025 & $563,000 in sales for the first quarter of 2026 while expanding its customer base.
  • The company anticipates full enrollment in the TIGeR-PaC trial in the near term with final data expected in mid to late 2027.
  • RenovoRx's IAG combination product candidate has received Orphan Drug Designation for pancreatic & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • A replay of the webcast will be available at the company's investor relations website after the live event.